PD-1 and CTLA-4: Two checkpoints, one pathway?

被引：17
|
作者：
Walker, Lucy S. K. [1 ]
机构：
[1] UCL, Div Infect & Immun, Inst Immun & Transplantat, Royal Free Campus, London NW3 2PF, England
来源：
SCIENCE IMMUNOLOGY | 2017年 / 2卷 / 11期
基金：
英国医学研究理事会;
关键词：
T-CELLS; CD28;
D O I：
10.1126/sciimmunol.aan3864
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
    Hao Zhang
    Ziyu Dai
    Wantao Wu
    Zeyu Wang
    Nan Zhang
    Liyang Zhang
    Wen-Jing Zeng
    Zhixiong Liu
    Quan Cheng
    Journal of Experimental & Clinical Cancer Research, 40
  • [22] The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix
    Mobarki, M.
    Karpathiou, G.
    Da Cruz, V.
    Chauleur, C.
    Forest, F.
    Peoc'h, M.
    VIRCHOWS ARCHIV, 2017, 471 : S80 - S80
  • [23] Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility
    Santoso, Budi
    Sa'adi, Ashon
    Dwiningsih, Sri Ratna
    Tunjungseto, Arif
    Widyanugraha, Muhammad Yohanes Ardianta
    Mufid, Alfin Firasy
    Rahmawati, Nanda Yuli
    Ahsan, Fadhil
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2020, 84 (04)
  • [24] OPTIMIZATION OF A FLOW CYTOMETRY PROTOCOL FOR PD-1/CTLA-4 IMMUNE CHECKPOINTS RECEPTORS DETECTION IN COLORECTAL CANCER TUMOUR MICROENVIRONMENT
    Zamfir, Marius
    Hudita, Ariana
    Mardare, Mara
    Bondoc, Irina
    Vacarasu, Andrei
    Tanase, Bogdan Cosmin
    Burcea-Dragomiroiu, George Traian Alexandru
    Litescu, Mircea
    Voiosu, Theodor
    Galateanu, Bianca
    Lambert, Claude
    Ginghina, Octav
    FARMACIA, 2023, 71 (02) : 367 - 374
  • [25] PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon, Tawee
    Gray, Jhanelle E.
    Antonia, Scott J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (03) : 305 - 312
  • [26] CTLA-4: Checkpoints beyond the membrane
    Buchan, Sarah L.
    MOLECULAR THERAPY, 2024, 32 (02)
  • [27] Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
    Marek Z. Wojtukiewicz
    Magdalena M. Rek
    Kamil Karpowicz
    Maria Górska
    Barbara Polityńska
    Anna M. Wojtukiewicz
    Marcin Moniuszko
    Piotr Radziwon
    Stephanie C. Tucker
    Kenneth V. Honn
    Cancer and Metastasis Reviews, 2021, 40 : 949 - 982
  • [28] At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
    Intlekofer, Andrew M.
    Thompson, Craig B.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2013, 94 (01) : 25 - 39
  • [29] A pan-cancer study of PD-1 and CTLA-4 as therapeutic targets
    Cai, Zongqiang
    Ang, Xiaojie
    Xu, Zekun
    Li, Shiqing
    Zhang, Jianglei
    Pei, Changsong
    Zhou, Feng
    TRANSLATIONAL CANCER RESEARCH, 2021, 10 (09) : 3993 - 4001
  • [30] Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
    Qin, Shuang
    Xu, Linping
    Yi, Ming
    Yu, Shengnan
    Wu, Kongming
    Luo, Suxia
    MOLECULAR CANCER, 2019, 18 (01)
12345